Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of AERAS-402 in HIV-infected, BCG-vaccinated Adults With CD4+ Lymphocyte Counts Greater Than 350 Cells/mm3.
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2016
At a glance
- Drugs Tuberculosis vaccine (Primary)
- Indications Tuberculosis
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
- 28 Mar 2011 Planned End Date changed from 1 May 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History